Ampsource Biopharma Shanghai Inc.

Pharmab, Inc.

Furen Pharmaceutical Group Co., Ltd

Kaifeng Pharmaceutical (Group) Co., Ltd.

Naichao Sun

Qiang Li

Yuanli Li

Yongjuan Gao

Si Ruo Chen

Xinlu Ma

Yuncheng Zheng

Lu Yang

Zhu Wang

Zhao Dong

Zirui Li

Wenwen Wang

Qilei Wang

Shuya Wang

Jie Gao

Zijia Ren

Zhi Li

Ming Jiang

Wenchen Zhu

Lirui Wang

Chenggong Zhu

Songlin Zhu

Hongsheng Su

Luyan Zhu

Xiaoshan Wang

Bin Liu

A linker peptide for constructing a fusion protein. The linker peptide comprises a flexible peptide and a rigid peptide. The flexible peptide consists of one or more flexible units. The rigid peptide consists of one or more rigid units. The flexible unit comprises two or more amino acid residues selected from Gly, Ser, Ala, and Thr. The rigid unit comprises a human chorionic gonadotropin &#x3b2;-subunit carboxy-terminal peptide (CTP) bearing a plurality of glycosylation sites. The linker peptide can more effectively eliminate mutual steric hindrance of two fusion molecules, decreasing a reduction/loss of polymerization or activity resulting from improper folding of an active protein or a conformational change. On the other hand, the negatively charged, highly sialylated CTP can resist renal clearance, further prolonging a half-life of a fused molecule and enhancing bioavailability of a fused protein. Furthermore, a protective effect of a glycosylated side chain CTP can lower the protease sensitivity of the linker peptide, making a linker region of the fusion protein less degradable.

Linker peptide for constructing fusion protein

A highly glycosylated human blood-clotting factor VIII (FVIII) fusion protein, and a manufacturing method and application of same. The fusion protein comprises, from the N-terminus to the C-terminus, a human (FVIII), a flexible peptide connector, at least one rigid unit of a human chorionic gonadotropin &#x3b2;-subunit carboxyl terminal peptide, and a half-life extending portion (preferentially selected from a human IgG Fc variant). The fusion protein has a similar level of biological activity as a recombinant (FVIII) and an extended in vivo half-life, thereby improving pharmacokinetics and drug efficacy.

Highly glycosylated human blood-clotting factor VIII fusion protein, and manufacturing method and application of same

Growing community of inventors

Shanghai, China

Naichao Sun